Market news

Health Catalyst is back in focus after analysts revised fair value from about US$2.10 to roughly US$1.83 per share, which points to a more cautious stance on the stock. Recent research has shifted from earlier optimism with price targets in the US$2 to US$3 range to current levels closer to US$1.80, as analysts weigh execution risks around churn, divestitures and the durability of growth in its health technology offerings. In this article, you will see how these changing targets fit into the...

Detailed price information for Marketaxess Holdings (MKTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Kohl brings public-company leadership and a record of successful transformation; Ben Albert to continue as Chief Business OfficerSALT LAKE CITY, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst” or the “Company,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Simeon Kohl has been appointed Chief Executive Officer (CEO) and President and a member of the Company’s Board of Directors,

SALT LAKE CITY, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior...

A number of stocks fell in the afternoon session after Bloomberg reported that Anthropic’s preliminary second-quarter revenue topped $11.5 billion.

Health Catalyst’s second quarter was marked by a notable decline in sales, which management attributed primarily to the ongoing impact of client migrations and a reduction in lower-margin services. The company’s decision to divest Vitalware, its revenue cycle management business, was described by CEO Ben Albert as necessary to focus on areas of highest conviction, despite the near-term revenue impact. Albert acknowledged the structural challenges facing health systems and emphasized that the div

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.

Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations.

Why Health Catalyst (HCAT) Shares Are Trading Lower Today

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report came out

Health Catalyst stock fell after hours after reporting Q2 results and issuing weaker third-quarter revenue guidance.

Health Catalyst (NASDAQ:HCAT) reported second-quarter 2026 revenue above the high end of its guidance range and adjusted EBITDA at the high end of its outlook, while outlining a strategic shift following the July 31 divestiture of its Vitalware and Med-Metrix businesses. Chief Executive Officer Ben

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings came out

Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 12.7% year on year to $70.49 million. On the other hand, next quarter’s revenue guidance of $55.5 million was less impressive, coming in 10.7% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

SALT LAKE CITY, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for...

Health Catalyst (HCAT) Q2 Earnings Report Preview: What To Look For

A number of stocks jumped in the afternoon session after the software sector caught a massive tailwind, fueled by easing geopolitical tensions and a fresh wave of AI-driven M&A.

Detailed price information for Health Catalyst Inc (HCAT-Q) from The Globe and Mail including charting and trades.

A number of stocks fell in the afternoon session after sentiment continued to weaken as tech stocks faced a dual headwind of deteriorating macro conditions and an unwinding of retail leverage.

Health Catalyst (NASDAQ:HCAT) stockholders approved three of four proposals presented at the company’s 2026 annual meeting, including the election of two directors, ratification of the company’s auditor and an advisory vote on executive compensation. A proposal to phase out the company’s classified

A number of stocks fell in the afternoon session after President Trump declared the Iran ceasefire "over" and threatened renewed strikes, sending oil higher and bond yields up in a session that punished high-multiple tech.